OTC : DNVVF

Deinove S.A.

$0.5 USD

$0 (0.0%)

Volume
1.9K
Average Volume
0
Market Capitalization
$0
P/E Ratio
-0.11
Dividend Yield
0.00%
Price Target
Year High
$0.58
Year Low
$0.47
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.36
Company Overview

OTC

Alexis Rideau

Biotechnology

Healthcare

DNVVF

44

FR

USD

https://www.deinove.com

33 4 48 19 01 00

N/A

N/A

Liquidity Metrics

-0.49

1.36

1.36

0.89

0.00

Sales & Valuation

-$

3.09

-0.06

-0.18

-0.22

Profitability

-$

-1904.90%

-2150.41%

60.55%

-74.55%

P/E Metrics

-0.11

0.00

0.00

Analyst Price Target & Rating

N/A

0/5

0 Analysts

%

Financial Health Scores

No financial score data available.

Key Metrics (TTM)

$3.61M

9.85

-0.52

1.36

60.55%

-97.26%

-922.43%

-552.96%

-127 days

Company Executives
Name Title
Michael Mourez Chief Innovation Officer
Alexis Rideau Chief Executive Officer
Georges Gaudriault Chief Scientific Officer
Yannick Pletan Chief Medical Officer & Independent Director
Mario Alcaraz Chief Financial & Admin. Officer
Miroslav Radman Co-Founder & Member of Scientific Advisory Board
Johane Rinaldi Chief HR Officer
Poll Results

No votes yet today — be the first to share your view!

About Deinove S.A. (OTC:DNVVF) Stock

Based in Grabels, France, and established in 2006, DEINOVE S.A. operates as a biotechnology firm dedicated to the discovery, development, and production of microbial-derived compounds. These innovative solutions cater to the global health, nutrition, and cosmetics industries. Among its pharmaceutical developments, the company's leading antibiotic candidate is DNV3837, currently undergoing Phase II clinical trials for the treatment of Clostridioides difficile infections. DEINOVE's diverse portfolio also extends to the personal care sector, featuring several key active ingredients. These include PHYT-N-Resist, an anti-aging component for cosmetics; Luminity, a carotenoid-based ingredient known for its potent antioxidant properties and ability to absorb blue light; HEBELYS, a natural active s ... ubstance derived from Sphingomonas fermentation; and BIOME Oléoactif, a post-biotic extract designed to rebalance skin microbiota through its prebiotic effects. Beyond these, the company is also formulating a method for creating natural ingredients intended for animal feed. To support its various endeavors, DEINOVE S.A. maintains significant partnership agreements with organizations such as bioMérieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Oléos-Hallstar, Greentech, and Avril.

Frequently Asked Questions

What is the current Deinove S.A. (DNVVF) stock price?

Deinove S.A.(OTC:DNVVF) stock price is $0.5 in the last trading session. During the trading session, DNVVF stock reached the peak price of $0.58 while $0.4706 was the lowest point it dropped to. The percentage change in DNVVF stock occurred in the recent session was 0.0% while the dollar amount for the price change in DNVVF stock was $0.

DNVVF's industry and sector of operation?

The OTC listed DNVVF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of DNVVF?

Michael Mourez | Chief Innovation Officer
Alexis Rideau | Chief Executive Officer
Georges Gaudriault | Chief Scientific Officer
Yannick Pletan | Chief Medical Officer & Independent Director
Mario Alcaraz | Chief Financial & Admin. Officer

How many employees does DNVVF have?

Number of DNVVF employees currently stands at 44. DNVVF operates from Cap Sigma, Grabels, None 34790, FR.

Link for DNVVF official website?

Official Website of DNVVF is: https://www.deinove.com

How do I contact DNVVF?

DNVVF could be contacted at phone #33 4 48 19 01 00 and can also be accessed through its website. DNVVF operates from Cap Sigma, Grabels, None 34790, FR.

How many shares of DNVVF are traded daily?

The average number of DNVVF shares traded daily for last 3 months was 0.

What is the market cap of DNVVF currently?

The market value of DNVVF currently stands at $0 with its latest stock price at $0.5